Home > Publications database > Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies. > print

001     148398
005     20240229112702.0
024 7 _ |a 10.1186/s40425-019-0828-1
|2 doi
024 7 _ |a pmid:31806053
|2 pmid
024 7 _ |a altmetric:72369529
|2 altmetric
037 _ _ |a DKFZ-2019-02953
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Wagner, Nikolaus B
|0 0000-0003-4708-2886
|b 0
|e First author
245 _ _ |a Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies.
260 _ _ |a London
|c 2019
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1576240785_12740
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies.
536 _ _ |a 311 - Signalling pathways, cell and tumor biology (POF3-311)
|0 G:(DE-HGF)POF3-311
|c POF3-311
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Weide, Benjamin
|b 1
700 1 _ |a Gries, Mirko
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Reith, Maike
|0 P:(DE-He78)20246d15b713462495c9cec21a61c7da
|b 3
700 1 _ |a Tarnanidis, Kathrin
|0 P:(DE-He78)0acd2b06b647ba4fff149a3c0eb463bf
|b 4
700 1 _ |a Schuermans, Valerie
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Kemper, Charlotte
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Kehrel, Coretta
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Funder, Anne
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Lichtenberger, Ramtin
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Sucker, Antje
|b 10
700 1 _ |a Herpel, Esther
|b 11
700 1 _ |a Holland-Letz, Tim
|0 P:(DE-He78)457c042884c901eb0a02c18bb1d30103
|b 12
700 1 _ |a Schadendorf, Dirk
|b 13
700 1 _ |a Garbe, Claus
|b 14
700 1 _ |a Umansky, Viktor
|0 P:(DE-He78)38be34240daf8b47325afc7910e77f7b
|b 15
700 1 _ |a Utikal, Jochen
|0 P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3
|b 16
700 1 _ |a Gebhardt, Christoffer
|0 P:(DE-He78)d239d6a28875058b40c13266babadb58
|b 17
|e Last author
773 _ _ |a 10.1186/s40425-019-0828-1
|g Vol. 7, no. 1, p. 343
|0 PERI:(DE-600)2719863-7
|n 1
|p 343
|t Journal for ImmunoTherapy of Cancer
|v 7
|y 2019
|x 2051-1426
909 C O |o oai:inrepo02.dkfz.de:148398
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 0000-0003-4708-2886
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)20246d15b713462495c9cec21a61c7da
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)0acd2b06b647ba4fff149a3c0eb463bf
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)457c042884c901eb0a02c18bb1d30103
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)38be34240daf8b47325afc7910e77f7b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 17
|6 P:(DE-He78)d239d6a28875058b40c13266babadb58
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-311
|2 G:(DE-HGF)POF3-300
|v Signalling pathways, cell and tumor biology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2019
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J IMMUNOTHER CANCER : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J IMMUNOTHER CANCER : 2017
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 0
920 1 _ |0 I:(DE-He78)A370-20160331
|k A370
|l KKE Dermatoonkologie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)A370-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21